<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323804</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS HC15 NRfi</org_study_id>
    <secondary_id>2005-002937-11</secondary_id>
    <nct_id>NCT00323804</nct_id>
  </id_info>
  <brief_title>Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop
      liver fibrosis leading to cirrhosis. Maintenance low dose pegylated interferon therapy of
      fibrosis is currently under investigation in large multicenter trials. The aim of our study
      is to assess if peginterferon alpha2b plus ribavirin is more efficient than peginterferon
      alpha2b alone. 454 patients will be randomized between the 2 arms and the efficacy will be
      assessed, after 3 years of treatment, on Metavir liver fibrosis score improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 45% of patients with chronic hepatitis C do not respond to pegylated
      interferon/ribavirin combination therapy. These patients are prone to develop liver fibrosis
      leading to cirrhosis and its complications. Interferon has proven to be efficient in liver
      fibrosis treatment even in case of virological non response. Maintenance low dose pegylated
      interferon therapy is currently under investigation in large multicenter trials. The aim of
      our study is to assess wether peginterferon alpha 2 b (0.5 µg/kg/week) plus ribavirin
      (800-1200 mg according to body weight) is more efficient than peginterferon alpha 2 b alone
      in a long term 3 years treatment of liver fibrosis. 454 patients, non responders (VHC RNA
      positive after 24 weeks of treatment or absence of ≥ 2 log HCV RNA drop after 12 weeks of
      treatment) to a previous peginterferon/ribavirin antiviral treatment will be randomized
      between the 2 arms, with a double-blind masking of ribavirin. The efficacy will be assessed
      on Metavir liver fibrosis score improvement between pre and post therapeutic liver biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.</measure>
    <time_frame>Screen visit and M36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of the Metavir scoring on the end-of-study biopsy</measure>
    <time_frame>M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of the Chevallier fibrosis score</measure>
    <time_frame>Screen visit and M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the area of fibrosis between the inclusion and the end-of -study biopsies</measure>
    <time_frame>Screen visit and M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis serum markers</measure>
    <time_frame>Screen, day0, M6, M12, M24, M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver elasticity before and after treatment</measure>
    <time_frame>Screen,M12, M24, M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment and quality of life</measure>
    <time_frame>day0, M6, M12, M24, M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of occurrence of hepatic complications and/or liver transplantations</measure>
    <time_frame>Day 0 to M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the hepatitis C viral load</measure>
    <time_frame>Screen to M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with loss of detectable hepatitis C virus RNA</measure>
    <time_frame>Day 0 to M36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin (RBV) arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of ribavirin capsules 200 mg, weight-based daily dose ( &lt;75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin-placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( &lt;75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b</intervention_name>
    <description>PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36</description>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin (RBV) arm</arm_group_label>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin-placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36</description>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin (RBV) arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin-Placebo</intervention_name>
    <description>Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36</description>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin-placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18

          -  With a hepatitis C virus infection (HCV RNA and anti-HCV antibodies in serum)

          -  Not responders to a previous antiviral treatment using the interferon plus ribavirin
             combination

          -  With a wash-out of treatment for at least 6 months

          -  With an active chronic hepatitis C and a Metavir fibrosis score ≥ 2

          -  Serum ALT levels &gt; upper limit of the laboratory on two occasions within 6 months
             before inclusion

          -  Accepting to undergo a liver biopsy at the end of the study

          -  Negative pregnancy test for women

          -  With a social security cover

          -  Written informed consent

        Exclusion Criteria:

          -  History of hepatic complications

          -  History of transplantation

          -  History of severe seizures

          -  History of severe psychiatric disorders

          -  Drug addiction within the last 12 months

          -  Associated condition susceptible to be responsible for liver fibrosis

          -  Hepatocellular carcinoma

          -  Cardiovascular disease unstable under treatment

          -  Uncontrolled diabetes

          -  Retinopathy

          -  Thyroid disease unstable under treatment

          -  Epilepsy and/or central nervous system functional disorders

          -  Autoimmune disease

          -  Regular alcohol consumption

          -  Pregnancy, breast-feeding or absence of contraception

          -  Haemoglobin &lt;12 g/dl

          -  platelets &lt;50000/mm3

          -  Neutrophils &lt; 1200/ mm3

          -  Severe hepatocellular failure (prothrombin index lower than 60%)

          -  Renal failure (creatinine clearance lower than 50 mL/Mn)

          -  Associated immunosuppressive drugs, corticosteroids, antiviral drugs (other than study
             ones)

          -  Treatment with drugs likely to have an effect on fibrosis

          -  Anticonvulsants

          -  Inability to tolerate interferon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Guyader, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bracops</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie et d'endoscopie digestive - CH du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatologie - Gastroentérologie - Cancérologie digestive - CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d' Hépatogastroentérologie - Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie et d'Assistance nutritive - Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Pierre OUDOT</name>
      <address>
        <city>Bourgoin-Jallieu</city>
        <zip>38317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatologie - Gastroentérologie - Nutrition -Hôpital de la Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Châteauroux</city>
        <zip>36000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CHU d'ESTAING</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Foie et de l'appareil Digestif - Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département d'Hépatogastroentérologie - CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CHRU - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hotel de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH Montélimar</name>
      <address>
        <city>Montelimar</city>
        <zip>26200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital de la Source</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie, Clinique médicale B - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpita Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maintenance therapy</keyword>
  <keyword>Non-responder patients</keyword>
  <keyword>Ribavirin/peginterferon combination therapy</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

